Cambridge Neuropsychological Test Automated Battery

Digital Endpoint Development for Alzheimer's Disease: The Importance of Patients as Partners, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, May 3, 2023
Cambridge Neuropsychological Test Automated Battery, Drug development, NIBR, Biomedical Research, Tapestry (DHT), Associate, Patient, Digital, Health, Alzheimer's disease, Medical imaging

TORONTO, May 3, 2023 /PRNewswire-PRWeb/ -- Digital health technologies (DHTs) like smartphones and wearable sensors hold great promise to advance drug development and discovery in neurodegenerative diseases, particularly Alzheimer's disease. Through objective, continuous, remote capture of real-world outcomes, DHTs have the capacity to measure the impact of novel treatments on how patients with Alzheimer's disease feel and function in their real-world environments, which, in turn, enables the development of drugs that improve aspects of health that matter most to patients. A digital endpoint derived from DHTs thus gives deeper insight on a patient's health.

Key Points: 
  • In this free webinar, learn about how patient engagement can enhance digital endpoint development in Alzheimer's disease clinical trials.
  • To ensure the development of patient-centric endpoints in Alzheimer's disease drug development, engaging patients as partners throughout the process of digital endpoint development is critical.
  • In this webinar, the featured speakers bring together stakeholders representing the perspectives of pharma, technology developers, and most importantly, patients.
  • Register for this webinar today to understand how patient engagement can enhance digital endpoint development in Alzheimer's disease clinical trials.

PLT Introduces Novel, Botanical Cognitive Performance Ingredient with a Broad Set of Benefits

Retrieved on: 
Monday, February 27, 2023
Recognition memory, Female, Athens insomnia scale, Overalls, Learning, Function (mathematics), Ellagic acid, Produce traceability, Episodic, Long-term memory, Amyrin, Brain, BDNF, Episodic memory, Innovation, Memory, Gallic acid, Brain-derived neurotrophic factor, Rate, Male, Short-term memory, PLT, PAI, Concentration, Learning rate, Theory, Working memory, Cambridge Neuropsychological Test Automated Battery, Ageing, Nursing, Pharmaceutical industry, CANTAB, Boswellia, RD, Recognition

MORRISTOWN, N.J., Feb. 27, 2023 /PRNewswire/ -- PLT Health Solutions, Inc is launching a novel ingredient to support a broad range of cognitive performance abilities. Called Nutricog® Cognitive Performance Complex, it is a patented combination of Haritaki (Terminalia chebula) and Boswellia (Boswellia serrata) — standardized to gallic acid, ellagic acid and amyrins. In a randomized, double-blind, placebo-controlled clinical trial, users of Nutricog demonstrated significant improvements compared to placebo across multiple cognitive domains, including learning, memory, sustained attention, working memory and executive function, where increases in cognitive speed were seen concurrently with improvements in accuracy while multitasking. The earliest clinically significant benefits (memory and focus) for Nutricog were shown to start at just 15 days after commencing use. PLT is introducing Nutricog at Natural Products Expo West in March and at Vitafoods Europe in May.

Key Points: 
  • Called Nutricog® Cognitive Performance Complex, it is a patented combination of Haritaki (Terminalia chebula) and Boswellia (Boswellia serrata) — standardized to gallic acid, ellagic acid and amyrins.
  • According to Seth Flowerman, President & CEO of PLT Health Solutions, the new ingredient was developed in response to consumer interest in maximizing cognitive support as a quality-of-life issue.
  • "Today, we are seeing rapidly increasing interest in cognitive support for a broad range of lifestyle goals.
  • At PLT, we're very excited to be introducing Nutricog to the market after more than five years in development.

Cambridge Cognition and Luca Healthcare Announce a Strategic Partnership and an Exclusive Licensing Agreement to Commercialize Cambridge Cognition's Suite of Cognitive Assessment Tools and Brain Health Products for the China Market

Retrieved on: 
Tuesday, November 29, 2022
Even and odd functions, Dementia, University, Cambridge Neuropsychological Test Automated Battery, Cognition, Partnership, Biotechnology, API, Learning, Patient, Neurodegeneration, Biomarker, Ophthalmology, Research, Memory, Digital technology, Clinical trial, HIV disease progression rates, Toy, Pharmaceutical industry, Medical imaging

"We are delighted to enter this partnership with Luca Healthcare to deploy Cambridge Cognition's products in China.

Key Points: 
  • "We are delighted to enter this partnership with Luca Healthcare to deploy Cambridge Cognition's products in China.
  • A key component of this partnership brings the CANTABsuite of tools to the China commercial market.
  • Luca plans to make these tools available to the China market through the LucaPlex platform that serves theirpharmaceutical and commercial partners in China.
  • Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health.

Real-World Measurement of Cognition and Mood in Frontline COVID-19 Healthcare Workers, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Thursday, September 8, 2022
Entrepreneurship, COVID-19, R, Food, Cambridge Neuropsychological Test Automated Battery, Smartphone, Industry, Health, Stress, Cognition, Medical device, Pharmaceutical industry

TORONTO, Sep. 8, 2022  /PRNewswire-PRWeb/ -- Passive data collection through wearable technology and smartphones is increasingly being used to capture health-related data in real-world settings. The Stress and Recovery in Frontline Healthcare COVID-19 Workers Study, conducted by 4YouandMe alongside multiple partners, used wearable devices and smartphone apps for the real-world measurement of stress, health and well-being of healthcare workers facing the frontline of the COVID-19 pandemic between March and December 2020.

Key Points: 
  • In this free webinar, learn how to develop an analytical framework for measuring mood and cognition using data captured from wearables and smartphone assessments.
  • Attendees will learn how to approach setting up a study involving passive and active data collection in a real-world setting.
  • Register to gain insights into real-world measurement on mood and cognition with wearable devices in frontline COVID-19 healthcare workers.
  • For more information, or to register for this event, visit Real-World Measurement of Cognition and Mood in Frontline COVID-19 Healthcare Workers.

SpectrumX Appoints Chief Financial Officer and Non-Executive Director

Retrieved on: 
Tuesday, March 22, 2022
Biotechnology, Finance, Health, Professional Services, Pharmaceutical, GE Healthcare, GSK, NHS, Patent, Marketing, Health, Growth, CFO, Corporate finance, CEO, Kleinwort Hambros, Industry, Cambridge Neuropsychological Test Automated Battery, Institute, Cognition, Solution, Hypochlorous acid, IPO, Patient, Management, Pharmaceutical industry, Pfizer, Indivior

SpectrumX, a UK-based healthcare and pharmaceutical company, is pleased to announce it has appointed Barry Saint as Chief Financial Officer and Debra Leeves as Non-Executive Director as the company progresses towards its IPO.

Key Points: 
  • SpectrumX, a UK-based healthcare and pharmaceutical company, is pleased to announce it has appointed Barry Saint as Chief Financial Officer and Debra Leeves as Non-Executive Director as the company progresses towards its IPO.
  • Prior to that, he served as Global Director of Corporate Finance and Group Treasurer of FTSE-250 speciality pharmaceuticals group, Indivior, which was formed through a $1.4 billion demerger from Reckitt Benckiser.
  • Barry Saint, Chief Financial Officer of SpectrumX, commented: I am delighted to have joined SpectrumX at this crucial stage as we prepare for IPO and then life as a listed company.
  • Debra Leeves, Non-Executive Director of SpectrumX, added: SpectrumX is developing ground-breaking treatments for patients across the world and I am excited to be joining as the company pushes forward the market roll out of its proprietary HOCI formulations.

Decentralised Trials in Psychiatry: From Feasibility to Novel Insights, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, October 27, 2021
Depression, Innovation, Industry, List of Medknow Publications academic journals, CNS, Patient, Ministry of Research, Innovation and Science, Digital technology, Telehealth, Time, Cambridge Neuropsychological Test Automated Battery, Food, Cognition, Journal, Pharmaceutical industry

Telemedicine and digital technology offer the means to overcome these key barriers to recruitment and start building novel insights into patient function.

Key Points: 
  • Telemedicine and digital technology offer the means to overcome these key barriers to recruitment and start building novel insights into patient function.
  • Psychiatry stands to benefit from the decentralisation of trials, yet new technologies and new ways of working have yet to be widely adopted.
  • For more information, or to register for this event, visit Decentralised Trials in Psychiatry: From Feasibility to Novel Insights.
  • Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community.

Novel Digital Technologies and Biomarkers to Characterise Depression, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Tuesday, October 12, 2021
Depression, Doctor of Philosophy, Cognition, Ministry of Research, Innovation and Science, Biomarker, Industry, Translational medicine, Cambridge Neuropsychological Test Automated Battery, Frontiers, Patient, Food, Online shopping, Medical imaging

Novel digital technologies offer the potential for more objective and precise symptom detection, but which best characterise depression?

Key Points: 
  • Novel digital technologies offer the potential for more objective and precise symptom detection, but which best characterise depression?
  • In efforts to address this question, Novartis evaluated seven digital technologies spanning eye-tracking in the clinic to the daily use of a Cambridge Cognition mobile app at home.
  • Recently published in Frontiers in Psychiatry, the researchers covered:
    Which technologies are useful to distinguish between depressed and healthy subjects?
  • For more information, or to register for this event, visit Novel Digital Technologies and Biomarkers to Characterise Depression.